FEATURED PSYCHEDELIC STOCK ARTICLES

MindMed Begins Phase 2 Clinical Trial of LSD for Treating "Suicide Headaches"

MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.

TSI EDITOR | 2020-06-08

---

Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans Launch of Initial Medicinal Mushroom Based Product Line

AlphaMind Brands Inc is entering the functional mushrooms market.

TSI EDITOR | 2020-06-05

---

MindMed Launches Project Lucy Focused On LSD Experiential Therapy For Anxiety Disorders

MindMed has high hopes for its new LSD-based anxiety therapy.

TSI EDITOR | 2020-06-04

---

Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director

Numinus adds to its management team.

TSI EDITOR | 2020-06-03

---

MindMed Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

MindMed's Microdosing Division is expanding its ADHD clinical trial.

TSI EDITOR | 2020-06-02

---

Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing

Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.

TSI EDITOR | 2020-05-29

---

Numinus Announces 2020 Operational Plans to Scale

Newly-listed Numinus Wellness provides a corporate update.

TSI EDITOR | 2020-05-28

---

MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies

MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.

TSI EDITOR | 2020-05-27

---

Numinus Takes Off On Initial Day Of Trading

Numinus Wellness is a new psychedelics stock that is up over 300% on its initial day of trading.

TSI EDITOR | 2020-05-20

---

• Previous
• 1
• ...
• 9
• 10
• 11
• 12